Cyclosporine A at reperfusion reduces infarct size in pigs
about
9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotectionMyocardial reperfusion injury: looking beyond primary PCIIschaemic conditioning and targeting reperfusion injury: a 30 year voyage of discoveryThe mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotectionReduction of early reperfusion injury with the mitochondria-targeting peptide bendaviaTranslating novel strategies for cardioprotection: the Hatter Workshop Recommendations.Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion.Cyclosporine A reduces microvascular obstruction and preserves left ventricular function deterioration following myocardial ischemia and reperfusion.Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection?Cell death pathways in acute ischemia/reperfusion injury.Targeted Modification of Mitochondrial ROS Production Converts High Glucose-Induced Cytotoxicity to Cytoprotection: Effects on Anesthetic Preconditioning.Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent.What makes the mitochondria a killer? Can we condition them to be less destructive?Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis.Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective Peptide.Myocardial ischemia-reperfusion injury: a neglected therapeutic target.Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A.Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations.Clinical efforts to reduce myocardial infarct size--the next step.Pharmacological approaches to the treatment of oxidative stress-induced cardiovascular dysfunctions.Targeting mitochondria for cardioprotection: examining the benefit for patients.Mitochondrial potassium channels as pharmacological target for cardioprotective drugs.Treatment of Myocardial Ischemia/Reperfusion Injury by Ischemic and Pharmacological Postconditioning.Mitochondrial permeability transition in cardiac ischemia-reperfusion: whether cyclophilin D is a viable target for cardioprotection?Optimal timing of hypothermia in relation to myocardial reperfusion.Distinct cardioprotective mechanisms of immediate, early and delayed ischaemic postconditioning.Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion.Infarct size reduction by cyclosporine A at reperfusion involves inhibition of the mitochondrial permeability transition pore but does not improve mitochondrial respiration.Cardiomyocyte mitochondria as targets of humoral factors released by remote ischemic preconditioning.Cyclosporine A cardioprotection: mechanisms and potential for clinical application.Endoplasmic reticulum stress contributes to heart protection induced by cyclophilin D inhibition.Cyclosporine A at reperfusion fails to reduce infarct size in the in vivo rat heart.The antiarrhythmic dipeptide ZP1609 (danegaptide) when given at reperfusion reduces myocardial infarct size in pigs.Insulin Postconditioning Reduces Infarct Size in the Porcine Heart in a Dose-Dependent Manner.Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.Cyclosporine A, 2.5 mg/kg, does not reduce myocardial infarct size in a porcine model of ischemia and reperfusion.The impact of irreproducibility and competing protection from P2Y12 antagonists on the discovery of cardioprotective interventions.HIF-1 reduces ischaemia-reperfusion injury in the heart by targeting the mitochondrial permeability transition pore.β3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes.Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection
P2860
Q26750797-0DD5FF92-11D5-4B37-BE96-F3887AA437BBQ26991482-142AA113-BCD0-4A5D-86CE-01EEB8780406Q28072918-61A3C779-CA84-4520-A58B-9E212E70FEFAQ28248925-8344A5FB-1472-4BAE-947B-5EF6A04A38A9Q33919143-29E9E1A1-02D9-48E9-B9F2-533A20FCC54AQ34247485-809D77E5-D64A-4D27-9B76-CFD0EB5D9901Q34300508-65BAA6F6-E179-499C-8677-83679F175A33Q35126767-69AC037B-7DA6-4A80-A466-B49F752D8082Q35286339-8AEE124B-35D3-4B1F-91B6-DE08928E0B75Q35913808-BC29C706-20D6-4971-9FE7-C83E79EFB560Q36006400-35CBE253-1FD3-4167-A3BF-88E6A500E02CQ36024824-32CE8CF1-7B57-4098-915D-D228F8629846Q36099938-71C74897-E243-46A6-8F3A-9D07C64E9F36Q36147255-91E715DB-BB87-4DEE-9E5A-50065432E66CQ36366202-FF4B9C8D-494A-4520-99A7-2CD5CE82DCFFQ36497176-E35D9A72-2A9A-44AB-8578-C7E4A18CD3B1Q37160450-BFE1BF3F-F11D-4908-B386-3BAB4C6A91C7Q37738596-9D2CB08C-32D6-4478-886B-F4DE9FC41A3CQ37912861-652E119E-C05F-4C1A-AD4F-A4A7268D9AD9Q38089739-35ACD4C0-871B-4AD2-893D-BAF4EB01194AQ38206842-594F9C31-DA59-4F3B-B638-CFC5F0CAB61CQ38262884-EB65B800-2080-4E01-B991-5A8223F0534AQ38542449-83A35173-7B40-43D8-8831-EBA475551122Q39220742-81E80421-7254-440A-B639-C9D4382B6CB4Q39739258-88AC60C8-8354-4E88-B6CF-D6F8F9C5A4D4Q41755944-78ECA24D-E97B-47F5-BFC5-211EFEA8EF11Q41892420-6D215D46-4875-4B5E-96A9-2B8146FF795EQ41892475-EA9C1540-A6E5-40F4-BFDC-D2B64BD9A647Q42318959-A1AFA997-4A7E-428E-9F43-9D817317695CQ43086748-25D916CB-C8E5-43B3-9228-8C2D14F8E72CQ44278960-7D6A576E-15F0-4CA8-8094-5B3FCCF0256EQ47216016-48ABA230-CE42-4424-90AF-245496364A41Q47255415-DA4A232D-4F55-4C0E-A171-CC5D7D9B9FAFQ47291028-AC97BCC5-CEAD-4269-B882-73791996054BQ47350464-CCCFCD7A-BA5B-45C6-BE7F-0A0B8F0D51FFQ47376511-31BBBE86-4554-47F8-93DD-33EA91D98F31Q48649274-4BBF0A1F-19A5-4377-8536-B20C11FF7763Q54334859-E05DB4A3-7736-4A5A-85C1-E842A2D8E4BEQ54343158-CF42AE47-8771-4D94-9388-23E8E5FD322EQ57760906-F8FDFC4D-360C-426C-B5AD-2FE2B00521C4
P2860
Cyclosporine A at reperfusion reduces infarct size in pigs
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cyclosporine A at reperfusion reduces infarct size in pigs
@ast
Cyclosporine A at reperfusion reduces infarct size in pigs
@en
type
label
Cyclosporine A at reperfusion reduces infarct size in pigs
@ast
Cyclosporine A at reperfusion reduces infarct size in pigs
@en
prefLabel
Cyclosporine A at reperfusion reduces infarct size in pigs
@ast
Cyclosporine A at reperfusion reduces infarct size in pigs
@en
P2860
P1476
Cyclosporine A at reperfusion reduces infarct size in pigs
@en
P2093
Andreas Skyschally
Gerd Heusch
P2860
P356
10.1007/S10557-010-6219-Y
P577
2010-02-01T00:00:00Z